đAre you attending the upcoming @EASL Congress 2024, the home of Hepatology, from 5-8 June in Milan, Italy!
Donât miss the opportunity to meet the @Vivet Therapeutics leadership team who will be in attendance and presenting a poster on its Phase 1/2 GATEWAY trial, evaluating the safety, pharmacodynamics and efficacy of its lead program VTX-801 for the treatment of #WilsonDisease.
Join us at booth đN1, where our CEO Jean-Philippe Combal, CSO Gloria Gonzalez-Aseguinolaza, our CMO Bernard Benichou, our Senior Project Manager Veronica Ferrer and Head of Clinical Operations and Patient Advocacy Representative Sonia Valero will be providing information on Vivetâs diversified recombinant AAV-based gene therapy pipeline consisting of two clinical and four pre-clinical assets to date!
Poster Presentation Details:
đ Title: Interim safety results of the ongoing international Phase I/II GATEWAY gene therapy trial with VTX-801 conducted in adult patients with Wilson Disease
đą Abstract Number: 164
đ Date: Wednesday June 5th
â Time: 08:30 â 18:00 CEST
The congress provides the perfect platform to connect with over 7,000 experts from all over the world to promote collaboration and drive innovation in #livertreatment.
